Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: leaptx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/29/2025 | Buy → Neutral | H.C. Wainwright | |
| 1/29/2025 | $9.00 → $1.25 | Outperform → Neutral | Robert W. Baird |
| 6/28/2024 | $8.00 | Buy | Rodman & Renshaw |
| 10/4/2021 | $6.00 | Buy | Mizuho |
| 9/14/2021 | $3.00 → $4.00 | Outperform | Raymond James |
CAMBRIDGE, Mass., Sept. 6, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the appointment of Richard L. Schilsky, MD, FASCO, FACP, FSCT to its Board of Directors, effective September 1, 2022. Dr. Schilsky brings over 40 years of experience in medicine and clinical research, specializing in new drug development and clinical trials for a wide range of cancers. "We are honored to welcome Dr. Schilsky, who brings a wealth of experience and deep knowledge to bolster Leap's drug development strategy," said Christopher Mirabelli, PhD, Chairman of Leap Therapeutics' Board. "He is a
8-K - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
10-Q - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
DEFA14A - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
DEF 14A - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
S-8 - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
10-K - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
8-K - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
8-K - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
SCHEDULE 13G/A - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
8-K - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)
4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)
4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)
4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)
4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)
4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)
4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)
4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)
4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)
4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)
CAMBRIDGE, Mass., May 13, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter of 2025. Leap Highlights: Reported positive data from the randomized, controlled Part B of the Phase 2 DeFianCe study of sirexatamab (DKN-01) plus bevacizumab and chemotherapy in second-line colorectal cancer (CRC) patients demonstrating significantly higher overall response rate (ORR) and longer progression-free survival (PFS) across DKK1-high and VEGF-naïve subgroupsHosted virtual key opinion leader (KOL) event featuring Zev A. Wainberg, MD, to further discuss the
U.S.-based Lankry brings over 20 years of financial leadership in biotech and healthcare with a proven track record of driving strategic growth, operational excellence, and capital market execution, including leading a U.S. IPO and M&A transaction REHOVOT, Israel, May 12, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, announced today the appointment of Shai Lankry as its Chief Financial Officer. "We are pleased to welcome Shai on board. His extensive experience in the U.S. and European biotech and pharma marke
FL-501 fully restored body composition and reversed key indicators of cachexia in preclinical models Findings confirm GDF-15's role in cachexia and support advancing FL-501 into the clinic CAMBRIDGE, Mass., April 25, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will present preclinical data of FL-501 in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting taking place April 25-30 in Chicago, Illinois. FL-501 is a potential best-in-class monoclonal antibody targeting growth differentiation factor 15 (GDF-15), a cytokine that is impli
Virtual KOL Event on Wednesday, April 23, 2025, at 2:30 p.m. ET CAMBRIDGE, Mass., April 15, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will host a virtual key opinion leader (KOL) event featuring Zev A. Wainberg, MD, Professor of Medicine at University of California, Los Angeles (UCLA) and co-director of the UCLA GI Oncology Program, on Wednesday, April 23, 2025 at 2:30 p.m. ET. To register, please click here. Dr. Wainberg will connect with Leap's Chief Medical Officer, Cynthia Sirard, MD, to discuss the unmet need and how sirexatamab (DKN-01) may improve upon the curr
Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024. Leap Highlights: Reported positive updated data from Part B of the Phase 2 DeFianCe study of sirexatamab (DKN-01) in second-line patients with advanced microsatellite stable (MSS) colorectal cancer (CRC) confirming:Statistically significant 32% higher overall response rate (ORR), 3.5 month longer progression-free survival (P
Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFS in second-line CRC patients with high DKK1 levels treated with sirexatamab plus bevacizumab and chemotherapy Statistically significant 22% higher ORR and 2.6 month longer PFSin patients who had not had prior anti-VEGF therapy Leap to host a conference call to present clinical data today, March 26, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today presented updated preliminary data from Part B of the DeFianCe study (NCT05480306), a Phase 2, open-label, g
35% objective response rate (ORR) in second-line colorectal cancer (CRC) patients treated with sirexatamab (DKN-01) plus bevacizumab and chemotherapy, compared to 23% ORR in the control arm DKK1 levels highly correlated with clinical activity in CRC population ORR benefit with sirexatamab observed across multiple potential Phase 3 CRC populations Preparations will begin for a registrational Phase 3 study in second-line CRC patients DisTinGuish Part C study in gastric cancer demonstrates activity in biomarker populations, but not the signal necessary to advance into Phase 3 Leap to host a conference call to present clinical data today, January 28, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass., Jan.
CAMBRIDGE, Mass., Jan. 6, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Leap Presentation Details: 43rd Annual J.P. Morgan Healthcare ConferenceDate: Wednesday, January 15, 2025Time: 2:15 p.m. Pacific Time A live webcast of the presentation may be accessed on the Investors page of the company's website at https://investors.leaptx.com/, where a replay of the events will also be available for a limited time. A
CAMBRIDGE, Mass., Nov. 26, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference in New York, NY. Leap Presentation Details: Piper Sandler 36th Annual Healthcare ConferenceDate: Wednesday, December 4, 2024Time: 4:00 p.m. Eastern Time A live webcast of the fireside chat may be accessed on the Investors page of the company's website at https://investors.leaptx.com/, where a replay of the events will also be available for a limited time
CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2024. Leap Highlights: Completed enrollment in the expanded randomized controlled Part B of the Phase 2 DeFianCe study evaluating DKN-01, Leap's anti-DKK1 monoclonal antibody, in combination with standard of care bevacizumab and chemotherapy in second-line patients with advanced colorectal cancer (CRC); data expected in mid-2025Patient follow-up continuing in the randomized controlled Part C of the Phase 2 DisTinGuish study evaluating DKN-01 in
SC 13G - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
SC 13G - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
SC 13G - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
SC 13G/A - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
SC 13G/A - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
SC 13G/A - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
SC 13G/A - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
SC 13G/A - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
SC 13G/A - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
SC 13G/A - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024. Leap Highlights: Reported positive updated data from Part B of the Phase 2 DeFianCe study of sirexatamab (DKN-01) in second-line patients with advanced microsatellite stable (MSS) colorectal cancer (CRC) confirming:Statistically significant 32% higher overall response rate (ORR), 3.5 month longer progression-free survival (P
Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFS in second-line CRC patients with high DKK1 levels treated with sirexatamab plus bevacizumab and chemotherapy Statistically significant 22% higher ORR and 2.6 month longer PFSin patients who had not had prior anti-VEGF therapy Leap to host a conference call to present clinical data today, March 26, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today presented updated preliminary data from Part B of the DeFianCe study (NCT05480306), a Phase 2, open-label, g
35% objective response rate (ORR) in second-line colorectal cancer (CRC) patients treated with sirexatamab (DKN-01) plus bevacizumab and chemotherapy, compared to 23% ORR in the control arm DKK1 levels highly correlated with clinical activity in CRC population ORR benefit with sirexatamab observed across multiple potential Phase 3 CRC populations Preparations will begin for a registrational Phase 3 study in second-line CRC patients DisTinGuish Part C study in gastric cancer demonstrates activity in biomarker populations, but not the signal necessary to advance into Phase 3 Leap to host a conference call to present clinical data today, January 28, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass., Jan.
CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2024. Leap Highlights: Completed enrollment in the expanded randomized controlled Part B of the Phase 2 DeFianCe study evaluating DKN-01, Leap's anti-DKK1 monoclonal antibody, in combination with standard of care bevacizumab and chemotherapy in second-line patients with advanced colorectal cancer (CRC); data expected in mid-2025Patient follow-up continuing in the randomized controlled Part C of the Phase 2 DisTinGuish study evaluating DKN-01 in
CAMBRIDGE, Mass., Aug. 12, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2024. Leap Highlights: Overall response rate (ORR) increases to 33% across all evaluable patients and 38% across evaluable patients with left-sided CRC in updated data from Part A of the Phase 2 DeFianCe study evaluating DKN-01 in combination with bevacizumab and chemotherapy in second-line patients with advanced colorectal cancer (CRC)Expanded the randomized controlled Part B of the DeFianCe study to 180 patients; enrollment expected to be comple
CAMBRIDGE, Mass., May 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2024. Leap Highlights: Completed $40 million private placement financing with participation from Gilead Sciences, Inc., a life sciences-focused investor, Samsara BioCapital, 683 Capital Partners, LP, Laurion Capital Management, and Rock Springs CapitalPresented clinical data from Part A of the Phase 2 DeFianCe study evaluating DKN-01 in combination with standard of care bevacizumab and chemotherapy in second-line patients with advanced colorectal ca
CAMBRIDGE, Mass., March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2023. Leap Highlights: Presented new clinical data from Part A of the Phase 2 DeFianCe study evaluating DKN-01 in combination with standard of care bevacizumab and chemotherapy in second-line patients with advanced colorectal cancer, at the 2024 ASCO Gastrointestinal Cancers SymposiumCompleted enrollment in the randomized controlled Part C of the Phase 2 DisTinGuish study evaluating DKN-01 in combination with tislelizumab and chemothe
30% ORR and 93% DCR across heterogenous second-line CRC patientstreated with DKN-01 plus bevacizumab and chemotherapy Subgroup analysis reveals greatest benefit in left-sided tumors, particularly rectal and rectosigmoid patients with 46% ORR, 100% DCR, and preliminary median PFS of 9.4 months. Leap to host conference call to report additional clinical data including further subgroup analyseson Tuesday, January 23, 2024 at 8:30 a.m. ET CAMBRIDGE, Mass., Jan. 16, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced new data from Part A of the DeFianCe study, a Phase 2 study evaluatin
CAMBRIDGE, Mass., March 24, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2022. Leap Highlights: Acquired Flame Biosciences, adding FL-301, a clinical stage anti-Claudin18.2 antibody, and preclinical antibody programs targeting Claudin18.2/CD137 and GDF15 to Leap's pipelinePresented clinical data from Part B of the Phase 2 DisTinGuish study of DKN-01 plus tislelizumab in gastroesophageal (GEA) cancer patients whose tumors express high levels of DKK1 (DKK1-high) and preclinical data supporting the activity o
Adds FL-301, clinical stage anti-Claudin18.2 antibody, and two preclinical antibody programs to Leap's pipeline Combined cash balance of approximately $115 million enhances runway to mid-2025, fully-funding advancement of DKN-01 and FL-301 Leap to host conference call at 9:00 a.m. ET today CAMBRIDGE, Mass., Jan. 17, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, and Flame Biosciences, Inc., a privately-held biotechnology company, today announced that the companies have entered into a definitive merger agreement pursuant to which Leap has acquired Flame and its assets, including FL-301, its c
H.C. Wainwright downgraded Leap Therapeutics from Buy to Neutral
Robert W. Baird downgraded Leap Therapeutics from Outperform to Neutral and set a new price target of $1.25 from $9.00 previously
Rodman & Renshaw initiated coverage of Leap Therapeutics with a rating of Buy and set a new price target of $8.00
Mizuho initiated coverage of Leap Therapeutics with a rating of Buy and set a new price target of $6.00
Raymond James reiterated coverage of Leap Therapeutics with a rating of Outperform and set a new price target of $4.00 from $3.00 previously
Robert W. Baird resumed coverage of Leap Therapeutics with a rating of Outperform and set a new price target of $5.00
Raymond James initiated coverage of Leap Therapeutics with a rating of Outperform and set a new price target of $3.50
Raymond James reiterated coverage of Leap Therapeutics with a rating of Outperform and set a new price target of $3.50 from $2.50 previously
Raymond James reiterated coverage of Leap Therapeutics with a rating of Outperform and set a new price target of $3.50 from $2.50 previously